Ultragenyx Pharmaceutical (RARE) Operating Margin (2016 - 2026)
Ultragenyx Pharmaceutical's (RARE) quarterly Operating Margin came in at 124.26% in Q1 2026, down 2139.0% year-on-year from 6.09% in Q1 2025, and down 127.37% on a QoQ basis from 54.65% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Operating Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 11 years of Operating Margin data on file, last reported at 124.26% in Q1 2026.
- On a quarterly basis, Operating Margin fell 2139.0% year-over-year to 124.26% in Q1 2026; TTM through Mar 2026 was 83.78%, a 326.0% increase from a year earlier, with the FY2025 full-year figure at 79.49%, up 1622.0% from the prior year.
- Operating Margin for Q1 2026 stood at 124.26%, down from 54.65% in the prior quarter.
- Over the last five years, Operating Margin for RARE reached as high as 54.65% in Q4 2025 and fell as low as 248.14% in Q3 2022.
- Historically, Operating Margin has averaged 123.86% across 5 years, with a median of 124.26% in 2026.
- Across the five-year window, Operating Margin slumped 13812 bps in 2022 and surged 10016 bps in 2023, its largest moves.
- Year by year, Operating Margin stood at 140.91% in 2022, then soared by 32 bps to 95.83% in 2023, then advanced by 22 bps to 74.28% in 2024, then grew by 26 bps to 54.65% in 2025, then tumbled by 127 bps to 124.26% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 124.26% in Q1 2026, 54.65% in Q4 2025, and 106.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn | -124.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.26% |
| Dec 31, 2025 | -54.65% |
| Sep 30, 2025 | -106.85% |
| Jun 30, 2025 | -64.80% |
| Mar 31, 2025 | -102.88% |
| Dec 31, 2024 | -74.28% |
| Sep 30, 2024 | -94.62% |
| Jun 30, 2024 | -79.14% |
| Mar 31, 2024 | -151.93% |
| Dec 31, 2023 | -95.83% |
| Sep 30, 2023 | -147.98% |
| Jun 30, 2023 | -136.61% |
| Mar 31, 2023 | -153.34% |
| Dec 31, 2022 | -140.91% |
| Sep 30, 2022 | -248.14% |
| Jun 30, 2022 | -158.48% |
| Mar 31, 2022 | -170.93% |
| Dec 31, 2021 | -122.99% |
| Sep 30, 2021 | -110.02% |
| Jun 30, 2021 | -95.17% |